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Abstract
MECP2 mutations are responsible for two different phenotypes in females, classical Rett
syndrome and the milder Zappella variant (Z-RTT). We investigated whether Copy Number
Variants (CNVs) may modulate the phenotype by comparison of array-CGH data from two
discordant pairs of sisters and four additional discordant pairs of unrelated girls matched by
mutation type. We also searched for potential MeCP2 targets within CNVs by ChIP-chip analysis.
We did not identify one major common gene/region, suggesting that modifiers may be complex
and variable between cases. However, we detected CNVs correlating with disease severity that
contain candidate modifiers. CROCC (1p36.13) is a potential MeCP2 target in which a duplication
in a Z-RTT and a deletion in a classic patient were observed. CROCC encodes a structural
component of ciliary motility that is required for correct brain development. CFHR1 and CFHR3,
on 1q31.3, may be involved in the regulation of complement during synapse elimination and were
found to be deleted in a Z-RTT but duplicated in two classic patients. The duplication of
10q11.22, present in two Z-RTT patients, includes GPRIN2, a regulator of neurite outgrowth and
PPYR1, involved in energy homeostasis. Functional analyses are necessary to confirm candidates
and to define targets for future therapies.
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Introduction
Rett syndrome (RTT, OMIM#312750) is an X-linked neurodevelopmental disorder
predominantly affecting females. In the classic form, after a period of normal development
(6-18 months), patients show growth retardation and regression of speech and purposeful
hand movements, with appearance of stereotyped hand movements, microcephaly, autism,
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seizures.1, 2 RTT syndrome has a wide spectrum of clinical phenotypes including: the
Zappella variant (Z-RTT), the early onset seizure variant and the congenital variant.3 Z-
RTT, firstly described by M. Zappella in 1992, represents the most common RTT variant. Z-
RTT is characterized by a recovery of the ability to speak in single words or third person
phrases and by an improvement of purposeful hand movements.4, 5 Z-RTT patients also
show milder intellectual disabilities (up to IQ of 50) and often normal head circumference,
weight and height respect to classic RTT.5
De novo mutations in the MECP2 gene (Xq28) account for the majority of girls with classic
RTT (95-97%) and for about half of cases with Z-RTT.5 The other two variants have been
associated with different loci, with mutations in CDKL5 (Xp22) found in the early onset
seizure variant and mutations in FOXG1 (14q13) found in the congenital variant.6-8
Only a few MECP2-mutated familial cases have been reported so far. Some cases have been
explained by skewing of X-inactivation towards the wild-type allele in an asymptomatic
carrier.9-11 In others cases, germline mosaicism has been a possible explanation.12-14
X-chromosome inactivation (XCI) is one important candidate factor modulating RTT
phenotype. However, studies performed on blood yielded conflicting results. In 2007,
Archer et al. performed the first systematic study of XCI in a large cohort of patients and
found a correlation between the degree and direction of XCI in leucocytes and RTT severity.
15
 However, it has been shown that XCI may vary remarkably between tissues.16,17 Thus,
the extrapolations of results based on sampling peripheral tissues, such as lymphocytes, to
other tissues, such as brain, may be misleading. The few studies performed on human RTT
brain tissues suggest that balanced XCI patterns are prevalent.16, 18-21 However, XCI has
been investigated in a limited number of brain regions and no definitive conclusions can be
drawn. In addition, previous studies demonstrated that other factors such as MECP2
mutation type and environment can influence RTT phenotype.5, 22,23 Since available data
cannot fully explain RTT variability, it is likely that a combination of different factors
cooperate in a complex manner to modulate the phenotype. In favor of this hypothesis, there
are cases of RTT sisters with identical MECP2 mutation, balanced X-inactivation, similar
environments and discordant phenotype (one classic and one Z-RTT sister).9,12
Copy Number Variations (CNVs) are segments of DNA ranging from kilobases (Kb) to
multiple megabases (Mb) in length that contain a variable number of copies compared with
the reference genome sequence. It has been demonstrated that CNVs are associated with
detectable differences in transcript levels for genes within the CNV breakpoints that are
predicted to have causative, functional effects in some cases. CNVs have been reported to be
associated with human diseases such as neurological and autoimmune disorders and cancer.
24
-
33
 CNVs, to a greater extent than Single Nuclotide Polimorphisms (SNPs), represent an
important source of variability in both phenotypically normal subjects and individuals with
diseases.34, 35 It is therefore reasonable to hypothesize that CNVs can modulate the
phenotypic expression of RTT syndrome.
In order to test this hypothesis, we analyzed by array-CGH two pairs of RTT sisters and four
additional pairs of unrelated RTT girls matched by mutation type showing discordant
phenotype (classic and Z-RTT). Complementary analysis of ChIP-chip data was also
performed to identify hypothetical MeCP2 targets included in the identified CNVs.
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Patients and Methods
Patients
From the Italian RTT database and biobank (www.biobank.unisi.it) we recruited two rare
familial cases with two RTT sisters with discordant phenotype: one classic (#897 and #138)
and one Z-RTT (#896 and #139).36 Blood DNA from these cases were screened by both
denaturing high-performance liquid chromatography (DHPLC) and multiplex ligation-
dependent probe amplification (MLPA) techniques to identify MECP2 mutations. The first
pair carry a large MECP2 deletion in exon 3 and exon 4, while the second pair have a late
truncating MECP2 mutation: c.1157del32. Clinical descriptions of these patients have been
reported in previous manuscripts.9,12 Furthermore, we selected four additional pairs
(#565/601, #185/119, #421/109, #402/368) of unrelated RTT patients with discordant
severity of RTT phenotype (classic and Z-RTT) and the same MECP2 mutation (c.
1163del26, p.R306C, c.1159del44, p.R133C) (Table 1 and 2). Chromosome X inactivation
(XCI), tested using the assay as modified from Pegoraro et al., revealed that all patients
show balanced XCI except for case #421 displaying a skewed XCI.37 All cases included in
the bank have been clinically evaluated by the Medical Genetics Unit of Siena. Patients were
classified in classic and RTT variant according to the international criteria.2, 38
Genomic DNA isolation
Blood samples were obtained after informed consent. Genomic DNA of the patients was
isolated from an EDTA preserved peripheral blood sample using the QIAamp DNA Blood
Kit according to the manufacturer’s protocol (Qiagen SPA, Milano, IT). Genomic DNA
from normal male and female controls was obtained from Promega (Promega Italia SRL,
Milano, IT). Ten micrograms (μgs) of genomic DNA from the patient (test sample) and the
control (reference sample) were sonicated. Test and reference DNA samples were
subsequently purified using affinity column purification (DNA Clean and Concentrator,
Zymo Research, Irvine, CA, USA) and the appropriate DNA concentrations were
determined by a DyNA Quant™ 200 Fluorometer (GE Healthcare, Piscataway, NJ. USA).
Array Comparative Genomic Hybridization
Array CGH analysis was performed using commercially available oligonucleotide
microarrays containing approximately 99,000 60-mer probes with an estimated average
resolution of 65 Kb. Probe locations are assigned according to position on the human
reference genome as shown of UCSC genome browser - NCBI build 36/hg18, March 2006
(http://genome.ucsc.edu).
DNA labeling was performed according to the Agilent Genomic DNA Labeling Kit Plus
using the Oligonucleotide Array-Based CGH for Genomic DNA Analysis 2.0v protocol
(Agilent Technologies Italia SpA, Milano IT). 3.5 μgs of genomic DNA from patients with
classical RTT and Z-RTT was mixed with Cy5-dNTP while 3.5 μgs of genomic DNA from
a control sample with known CNVs was mixed with Cy3-dNTP, as previously reported.39
The array was disassembled and washed according to the manufacturer protocol with wash
buffers supplied with the Agilent 105A kit. The slides were dried and scanned using an
Agilent G2565BA DNA microarray scanner (Agilent Technologies).
Array-CGH image and data analysis
Image analysis was performed using the CGH Analytics software v. 5.0.14 using the default
settings (Agilent Technologies). The software automatically first determines the
fluorescence intensities of the spots for both fluorochromes performing background
subtraction and data normalization, then compiles the data into a spreadsheet that links the
fluorescent signal of every oligo on the array to the oligo name, its position on the array and
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its position in the genome. The linear order of the oligos is reconstituted in the ratio plots
consistent with an ideogram. The ratio plot is arbitrarily assigned such that gains and losses
in DNA copy number at a particular locus are observed as a deviation of the ratio plot from
a modal value of 1.0.
Analysis of MeCP2 bound promoters within defined CNVs
Chromatin immunopreceipitation microarray (ChIP-chip) analysis of genome-wide
promoters was performed in a previous study.40 Briefly, MeCP2 ChIP was performed on
two replicate human SH-SY5Y neuroblastoma cultures differentiated by 48h treatment with
phorbal 12-myristate 13-acetate (PMA) and hybridized to a commercial genome wide
promoter microarray (Nimblegen, Wisconsin, USA). In this 1.5 kb promoter array, tiled
oligonucleotide probes extend 1.3 kb upstream and 0.2 kb downstream of the transcriptional
start sites of 24,275 human transcripts. Statistical analysis of promoter ChIP-chip data
indicated that 2600-4300 promoters were bound by MeCP2 with 1524 promoters common to
two replicate hybridizations. Promoters were ranked according to MeCP2 binding “hits”
based on ChIP-chip log2 values for the two arrays (MeCP2_B and MeCP2_C). In this way,
1 represents the strongest MeCP2 bound promoter out of 24,275 annotated genes. The data
reported in this paper have been deposited in the Gene Expression Omnibus (GEO)
database, www.ncbi.nlm.nih.gov/geo (accession no. GSE9568).
Analyses of phenotypically discordant RTT pairs resulted in 29 CNVs that included 67
candidate genes which could potentially modify RTT phenotype. The MeCP2 promoter
rankings were compared for the list of 67 candidate genes using all gene aliases. MeCP2
promoter levels could not be identified for 24 of the 67 CNV genes because these genes
were not annotated on the NimbleGen promoter array.
Results
Overall, we indentified 29 CNVs, 28 of them corresponding to known polymorphic regions
and one on 3q13.12 corresponding to an apparently private rearrangement duplicated in only
one Z-RTT patient (#119) (Table 1 and 2). Among the 29 CNVs, we considered 14 of them
as “unlikely modifiers” since they were apparently not associated with phenotypic severity
(Table 2). These include regions containing olfactory receptors and class II HLA molecules
that are not expected to directly correlate with the phenotypic variability related to classic/Z-
RTT phenotype. The remaining 15 CNVs were considered as “likely modifiers” (Table 1).
In three cases the copy number change was consistent with severity differences in at least
two pairs of RTT patients (Table 1) (Fig. 1). Genes included in these potential modifier
regions are listed and described in Table 3.
To determine if the CNVs found in phenotypically discordant RTT pairs contained possible
MeCP2 target genes, we compared promoter rankings of MeCP2 binding using promoter-
wide ChIP-chip analysis.40 The ranking from total number of genes from 1 to 24,134 is
shown for two replicate MeCP2-ChIP microarrays (MeCP2 B and MeCP2 C promoter hits
rank, Tables 1 and 2). Genes with promoters in the top 10% of MeCP2 promoter hits for at
least one replicate are indicated in bold. Among CNVs classified as “likely modifiers”,
ChIP-chip analysis identified potential MeCP2 target genes within the 1p36.13 (CROCC
gene whose duplication was found in the Z-RTT # 896 and deletion in the classic form
#402) and the 2p25.2 (TSSC1 gene whose deletion was found in the Z-RTT #896) regions.
Among CNVs classified as “unlikely modifiers”, ChIP-chip analysis identified potential
MeCP2 target genes on 14q11 (OR4Q3 and OR4Q1, deleted in a classic patient #138 and
duplicated in another classic patient #421) and on 16p11.2 (NFATC2IP and SPNS1,
duplicated in both a classic #897 and a Z-RTT patient #368).
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Discussion
In order to test the hypothesis that genes contained within common CNVs may modulate the
RTT phenotype, we analyzed by array-CGH two pairs of RTT sisters and four additional
pairs of unrelated RTT girls matched by MECP2 mutation type showing discordant
phenotype: classic and Z-RTT. Our study did not identify a single major common modifier
gene/region, suggesting that genetic modifiers may be complex and variable between cases
(Tables 1 and 2). In total we found 29 CNVs that were divided into two groups: “likely
modifiers” and “unlikely modifiers” (Tables 1 and 2).
Among the first group, the rearrangement on 1p36.13 includes CROCC (ciliary rootlet
coiled-coil) that represents an interesting potential modifier gene. This gene is duplicated in
the Z-RTT patient # 896 and deleted in the classical patient # 402, suggesting that change in
its expression may modulate RTT outcome. Moreover, according to ChIP-chip analysis,
CROCC could be a potential MeCP2 target gene (Table 1). CROCC encodes for a major
structural component (Rootletin) of the ciliary rootlet, a cytoskeletal-like structure in ciliated
cells which originates from the basal body at the proximal end of a cilium and extends
proximally toward the cell nucleus.41 In non-ciliated cells, a miniature ciliary rootlet is
located at the centrosome and does not project a fibrous network into the cytoplasm.41
Rootletin is expressed in retina, brain, trachea and kidney.41 Cilia generate specialized
structures that perform critical functions of several broad types: sensation, development,
fluid movement, sperm motility, and cell signaling. Their functional significance in tissues is
reflected in the severity and diversity of pathologies caused by defects in cilia. These include
anosmia, retinitis pigmentosa and retinal degeneration, polycystic kidney disease, diabetes,
neural tube defects and neural patterning defects, chronic sinusitus and bronchiectasis,
obesity, heterotaxias, polydactyly, and infertility.42 Defects in cilia are therefore underlying
causes of several diseases with pleiotropic symptoms.43 Several pleiotropic disorders
(Bardet-Biedl syndrome, Alstrom syndrome, Meckel-Gruber syndrome and Joubert
syndrome) caused by disruption of the function of cilia present mental retardation or other
cognitive defects as part of their phenotypic spectrum.44 The presence of cilia in different
types of neurons supports the notion that dysfunction in specific neuronal populations might
explain, at least in part, such defects.42, 45 If MeCP2 acts as a positive regulator of CROCC,
it can be hypothesized that higher protein levels due to the presence of three copies of the
gene may counteract the MECP2 mutation, while lower protein level due to single gene
copy may worsen the phenotype.
The CFHR gene family members (CFHR1 and CFHR3) located on 1q31.3 are duplicated in
classic girls ( #185 and #402) and deleted in Z-RTT (#368), suggesting that the phenotype
may benefit from the reduced expression of these proteins involved in complement
regulation.46 The complement system is a tightly controlled component of the host innate
immune defence. Imbalances in regulation of this system contribute to tissue injury and can
result in autoimmune diseases. In particular, CFHR1 and CFHR3 was previously associated
with hemolytic uremic syndrome (HUS) and age related macular degeneration (AMD).47-49
It is well known that the immune system participates in the development and functioning of
the CNS and an immune etiology for RTT and autism has been recently hypothesized.50
Interestingly, complement proteins have been demonstrated to be fundamental for CNS
synapse elimination.51 Morphological studies in postmortem brain samples from RTT
individuals described a characteristic neuropathology which included decreased dendritic
arborization, a reduction in dendritic spines, and increased packing density.52 It is therefore
possible that the protein product of CFHR could be involved in the regulation of synaptic
connections and that these genes could influence RTT severity.
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The duplication on 10q11.22, present in two Z-RTT patients (#139 and #368), includes two
interesting candidate modifier genes: GPRIN2 and PPYR1. GPRIN2 is highly expressed in
the cerebellum and interacts with activated members of the Gi subfamily of G protein α
subunits and acts together with GPRIN1 to regulate neurite outgrowth.53 PPYR1, also
named as neuropeptide Y receptor or pancreatic polypeptide 1, is a key regulator of energy
homeostasis and directly involved in the regulation of food intake. Previous studies have
reinforced the potential influence of PPYR1 on body weight in humans.54 Moreover, it has
been demonstrated that PPYR1 knockout mice display lower body weight and reduced white
adipose tissue.55 Thus, a higher level of PPYR1 expression due to gene duplication may
correlate with the higher body weight characterizing Z-RTT patients in respect to classic
RTT.5 In contrast, a recent study demonstrated that 10q11.22 gain is associated with lower
body mass index value in the Chinese population.56 However this CNV is much larger
respect to the one reported here and includes two additional genes.56
The 3q13.12 duplication found in a Z-RTT patient (#119) encompasses about 280 Kb and
does not contain interesting candidate RTT modifier genes. GUCA1C encodes for a
granulate cyclise activating protein expressed in retina and MORC1 encodes for a testis-
specific protein with a putative role in spermatogenesis. However it is known that CNVs can
also induce altered expression of genes that lie near the boundaries of the CNV and that this
effect can be as far as 2–7 Mb away from the breakpoints.57 Therefore we cannot totally
exclude a role for this CNV in modulating RTT phenotype.
The 1q42.12 region, duplicated in one Z-RTT patient (#896), includes ENAH. This gene
was identified as a mammalian homolog of Drosophila Ena and initially named Mena
(Mammalian enabled).58 It localizes to cell-substrate adhesion sites and sites of dynamic
actins assembly and disassembly. It is a member of the Ena/VASP family that also includes
VASP and EVL in vertebrates. Work carried out in Drosophila, C. elegant and mice showed
that these proteins participate in axonal outgrowth, dendrite morphology, synapse formation
and also function downstream of attractive and repulsive axon guidance pathways.59-61
Previous evidence shows that knocking out the three murine genes encoding ENA/VASP
proteins results in a blockade of axon fibre tract formation in the cortex in vivo, and that
failure in neuritis initiation is the underlying cause of the axonal defects.62,63 ENAH
therefore represents an interesting potential gene modifier in RTT. Further investigations are
necessary in order to test whether the duplication of ENAH gene in Z-RTT #896 effectively
corresponds with increased mRNA levels in brain and whether this mechanism is confined
to one pair of discordant girls or is a common mechanism in Z-RTT possibly throughout
SNP modulation.
The intersection of CNV and MeCP2 promoter binding analyses was useful in identifying
potential modifier genes for further investigation. However, genes with MeCP2 bound
promoters were not apparently enriched within the CNVs in the “likely” versus “unlikely”
modifier categories. MeCP2 binding is found more frequently in non-promoter regions when
analyzed by genomic tiling microarray to selected regions, so the analysis of promoters only
in identifying potential MeCP2 target genes was a limitation of this study.40 Further studies
to detect MeCP2 binding genome-wide in human neurons by Chip sequencing may reveal
additional insights.
A second limitation of this study is that the number of patients is too low to perform a
statistically significant analysis of CNVs in classic and Z-RTT and this is principally due to
the difficulty in recruiting Z-RTT cases. Furthermore, mRNA expression analysis of genes
within CNVs has not been performed because of a lack of sufficient blood RNA samples.
However, an analysis of transcript levels in blood would not be conclusive because the
genes within likely modifier CNVs exhibit tissue-specific expression in tissues other than
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blood cells. Our studies do suggest genes for further studies in animal models or in new
cellular models such as neurons derived from human induced pluripotent stem cells (iPS).
Moreover this study indicates possible candidate genes to test for functional SNPs in array-
CGH negative cases. In fact this study is focused on CNVs but SNPs could also play an
important role in determining RTT phenotypic variability. By candidate gene approach, this
has been already demonstrated for the p.Val66Met polymorphism in BDNF, even if with
contrasting results.64,65 The recent feasibility of exome sequencing will allow to yield
important results that will further improve the understanding of RTT phenotypic variability.
In conclusion, we present a novel approach for investigating genetic modifiers for RTT
severity by identifying CNVs different between pairs with discordant phenotype: classic and
Z-RTT. Further investigation using gene expression and/or statistical analysis in a larger
number of patients will be necessary to confirm these data and to define targets for future
therapeutic intervention.
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Figure 1.
Array-CGH ratio profiles. a) Array-CGH ratio profiles of CNV on 1p36.13 of #402 classic
RTT patient. On the left, the chromosome 1 ideogram. On the right, the log 2 ratio of the
chromosome 1 probes plotted as a function of chromosomal position. Copy number loss
shifts the ratio to the left. b) Array-CGH ratio profiles of CNV on 1q31.3 of #368 Z-RTT
patient. On the left, the chromosome 1 ideogram. On the right, the log 2 ratio of the
chromosome 1 probes plotted as a function of chromosomal position. Copy number loss
shifts the ratio to the left. c) Array-CGH ratio profiles of CNV on 10q11.22 of #139 Z-RTT
patient. On the left, the chromosome 10 ideogram. On the right, the log 2 ratio of the
chromosome 10 probes plotted as a function of chromosomal position. Copy number gain
shifts the ratio to the right.
Artuso et al. Page 11
J Hum Genet. Author manuscript; available in PMC 2012 January 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Artuso et al. Page 12
Ta
bl
e 
1
CN
V
s c
la
ss
ifi
ed
 a
s “
lik
el
y 
m
od
ifi
er
s”
 si
nc
e 
th
ey
 c
or
re
la
te
 w
ith
 p
he
no
ty
pi
c 
RT
T 
se
ve
rit
y.
Po
ly
m
or
ph
ic
 C
N
V
s
Br
ea
kp
oi
nt
s
(b
p)
G
en
e
co
n
te
nt
M
eC
P2
_B
pr
om
ot
er
 h
its
ra
n
k
M
eC
P2
_C
pr
om
ot
er
 h
its
 r
an
k
89
7 
C
/
89
6 
Z
(E
x 3
/4 
de
l)
13
8 
C
/
13
9 
Z
(c.
11
57
de
l32
)
56
5 
C
/
60
1 
Z
(c.
11
63
de
l26
)
18
5 
C
/
11
9 
Z
(p
.R
30
6C
)
42
1 
C
/
10
9 
Z
(c.
11
59
de
l44
)
40
2 
C
/
36
8 
Z
(p
.R
13
3C
)
1p
36
.1
3{
42
6 k
b}
16
,6
98
,9
06
-
17
,1
24
,5
54
ES
PN
P
13
82
2
22
69
0
D
up
 Z
D
el
 C
M
ST
P9
-
-
CR
OC
C
65
8
16
30
0
1q
31
.3
{5
5 k
b}
19
5,
01
1,
34
-
19
5,
06
5,
86
7
CF
HR
1
23
14
4
76
51
D
up
 C
A
m
p 
C/
D
el
 Z
CF
HR
3
20
25
3
69
94
1q
42
.1
2{
13
9 k
b}
22
3,
73
1,
55
-
22
3,
87
0,
81
9
EN
A
H
18
60
4
13
55
3
D
up
 Z
2p
25
.2
{4
00
 kb
}
3,
06
0,
97
5-
3,
46
0,
50
6
TS
SC
1
94
1
31
74
D
el
 Z
TT
C1
5
20
74
0
21
64
1
2q
37
.3
{1
41
 kb
}
24
2,
51
4,
59
-
24
2,
65
5,
97
3
/
-
-
D
el
 Z
3q
13
.1
2{
28
1 k
b}
11
0,
11
6,
09
-
11
0,
39
7,
43
3
GU
CA
1C
19
29
3
61
67
D
up
 Z
M
OR
C1
18
31
7
20
39
4
C3
or
f6
6
12
13
6
81
47
5p
15
.3
3{
85
 kb
}
76
3,
94
4-
84
8,
74
4
ZD
H
H
C1
1
43
49
13
28
4
D
up
 Z
6q
27
{2
10
 kb
}
16
8,
11
4,
26
-
16
8,
32
4,
00
2
M
LL
T4
-
-
D
up
 Z
C6
or
f5
4
23
89
66
71
K
IF
25
87
78
31
59
FR
M
D
1
15
80
0
10
53
0
7p
21
.3
{8
9 k
b}
11
,7
20
,9
01
-
11
,8
09
,7
63
TH
SD
7A
85
20
81
60
D
el
 Z
8q
21
.3
{8
7 k
b}
87
,1
36
,2
22
-
87
,2
22
,7
95
PS
KH
2
19
41
3
94
91
D
up
 C
A
TP
6V
OD
2
22
85
8
40
87
10
q1
1.
22
{1
72
 kb
}
46
,3
96
,1
63
-
46
,5
68
,4
96
GP
RI
N2
17
34
3
23
31
2
D
up
 Z
D
up
 Z
PP
Y
R1
16
72
2
98
12
14
q3
2.
33
{1
25
 kb
}
10
5,
70
8,
20
-
10
5,
83
3,
37
2
SL
K
14
76
9
10
23
6
D
el
 Z
CO
L1
7A
1
42
92
25
79
J Hum Genet. Author manuscript; available in PMC 2012 January 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Artuso et al. Page 13
Po
ly
m
or
ph
ic
 C
N
V
s
Br
ea
kp
oi
nt
s
(b
p)
G
en
e
co
n
te
nt
M
eC
P2
_B
pr
om
ot
er
 h
its
ra
n
k
M
eC
P2
_C
pr
om
ot
er
 h
its
 r
an
k
89
7 
C
/
89
6 
Z
(E
x 3
/4 
de
l)
13
8 
C
/
13
9 
Z
(c.
11
57
de
l32
)
56
5 
C
/
60
1 
Z
(c.
11
63
de
l26
)
18
5 
C
/
11
9 
Z
(p
.R
30
6C
)
42
1 
C
/
10
9 
Z
(c.
11
59
de
l44
)
40
2 
C
/
36
8 
Z
(p
.R
13
3C
)
15
q1
4{
49
 kb
}
32
,5
23
,2
41
-
32
,5
72
,3
15
/
-
-
D
el
 Z
16
p1
1{
20
0 k
b}
34
,3
99
,5
43
-
34
,5
39
,8
90
/
-
-
D
up
 Z
22
q1
3.
2{
49
 kb
}
41
,2
37
,7
31
-
41
,2
87
,0
60
SE
RH
L
-
-
D
up
 Z
SE
RH
L2
-
-
A
bb
re
vi
at
io
ns
: A
m
p,
 a
m
pl
ifi
ca
tio
n;
 C
N
V
s, 
co
py
 n
um
be
r v
ar
ia
nt
s; 
C,
 c
la
ss
ic
; D
el
, d
el
et
io
n;
 D
up
, d
up
lic
at
io
n;
 Z
, Z
-R
TT
B
ol
d 
nu
m
be
rs
 a
re
 in
 th
e 
to
p 
10
%
 o
f M
eC
P2
 p
ro
m
ot
er
 h
its
.
J Hum Genet. Author manuscript; available in PMC 2012 January 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Artuso et al. Page 14
Ta
bl
e 
2
CN
V
s c
la
ss
ifi
ed
 a
s “
un
lik
el
y 
m
od
ifi
er
s”
 si
nc
e 
th
ey
 w
er
e 
ap
pa
re
nt
ly
 n
ot
 a
ss
oc
ia
te
d 
w
ith
 p
he
no
ty
pi
c 
se
ve
rit
y.
Po
ly
m
or
ph
ic
 C
N
V
s
Br
ea
kp
oi
nt
s
(b
p)
G
en
e c
on
te
nt
M
eC
P2
_B
pr
om
ot
er
 h
its
ra
n
k
M
eC
P2
_C
pr
om
ot
er
 h
its
ra
n
k
89
7 
C
/
89
6 
Z
(E
x 3
/4 
de
l)
13
8 
C
/
13
9 
Z
(c.
11
57
de
l32
)
56
5 
C
/
60
1 
Z
(c.
11
63
de
l26
)
18
5 
C
/
11
9 
Z
(p
.R
30
6C
)
42
1 
C
/
10
9 
Z
(c.
11
59
de
l44
)
40
2 
C
/
36
8 
Z
(p
.R
13
3C
)
1q
44
{5
8 k
b}
24
6,
79
4,
52
2-
24
6,
85
2,
12
6
OR
2T
34
22
56
7
14
24
4
D
up
 Z
D
el
 C
D
el
 C
D
el
 Z
OR
2T
10
22
34
8
85
66
2p
11
{4
94
 kb
}
89
,4
01
,8
38
-
89
,8
95
,5
66
*
IG
KV
1-
16
D
-
-
D
el
 Z
3q
26
{1
04
 kb
}
16
3,
99
7,
22
8-
16
4,
10
1,
77
6
/
-
-
D
el
 C
D
el
 Z
D
el
 C
/
D
el
 Z
3q
29
{3
6 k
b}
19
6,
90
5,
76
7-
19
6,
94
2,
15
8
M
U
C2
0
17
72
7
12
87
3
D
up
 C
D
up
C/
D
up
Z
D
up
 C
D
up
 C
4q
13
.2
{1
08
 kb
}
69
,0
57
,7
35
-
69
,1
65
,8
14
U
GT
2B
17
21
71
9
18
33
6
D
up
 C
D
el
 Z
D
el
 C
6p
21
.3
2{
65
 kb
}
29
,9
39
,2
88
-
30
00
4,
63
6
H
CG
4P
6
D
el
 C
D
el
 Z
6p
21
.3
3{
77
 kb
}
32
,5
95
,4
02
-
32
,6
72
,9
83
H
LA
-D
RB
5
D
up
 Z
A
m
p 
C
A
m
p 
C/
A
m
p 
Z
H
LA
-D
RB
1
11
82
4
21
87
9
8p
11
.2
3{
14
3 k
b}
39
,3
56
,5
95
-
39
,4
99
,7
52
A
D
A
M
5P
14
07
0
29
16
D
up
 C
D
up
 C
*
A
m
p 
Z
A
m
p 
C/
A
m
p 
Z
A
m
p 
C/
A
m
p 
Z
10
q1
1.
22
{1
44
 kb
}
47
,0
17
,5
98
-
47
,1
61
,2
32
/
-
-
D
up
 C
D
up
 Z
D
up
 Z
14
q1
1{
86
0 k
b}
18
,6
24
,3
83
-
19
,4
84
,0
13
OR
11
H1
3P
D
el
 C
D
up
 C
OR
4Q
3
23
53
9
33
0
OR
4M
1
24
05
4
46
86
OR
4N
2
23
38
3
70
30
OR
4K
2
21
95
7
35
67
OR
4K
5
21
81
4
79
44
OR
4K
1
23
68
4
16
2
15
q1
1.
2{
72
7 k
b}
18
,8
10
,0
04
-
19
,5
37
,0
35
/
-
-
D
el
 C
D
el
 C
D
el
 Z
D
el
 C
16
p1
1.
2{
22
0 k
b}
28
,7
32
,2
95
-
28
,9
52
,2
18
A
TX
N
2L
-
-
D
up
 C
D
up
 Z
TU
FM
70
97
38
48
J Hum Genet. Author manuscript; available in PMC 2012 January 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Artuso et al. Page 15
Po
ly
m
or
ph
ic
 C
N
V
s
Br
ea
kp
oi
nt
s
(b
p)
G
en
e c
on
te
nt
M
eC
P2
_B
pr
om
ot
er
 h
its
ra
n
k
M
eC
P2
_C
pr
om
ot
er
 h
its
ra
n
k
89
7 
C
/
89
6 
Z
(E
x 3
/4 
de
l)
13
8 
C
/
13
9 
Z
(c.
11
57
de
l32
)
56
5 
C
/
60
1 
Z
(c.
11
63
de
l26
)
18
5 
C
/
11
9 
Z
(p
.R
30
6C
)
42
1 
C
/
10
9 
Z
(c.
11
59
de
l44
)
40
2 
C
/
36
8 
Z
(p
.R
13
3C
)
SH
2B
1
12
67
5
12
68
0
A
TP
2A
1
15
18
2
23
56
6
RA
BE
P2
10
29
8
16
79
4
CD
19
18
46
9
15
60
4
N
FA
TC
2I
P
23
32
6
16
27
SP
NS
1
13
93
20
31
7
LA
T
15
14
5
14
27
1
17
q2
1.
31
{1
63
 kb
}
41
,5
44
,2
24
-
41
,7
06
,8
70
K
IA
A
12
67
-
-
A
m
p 
C/
D
up
 Z
D
up
 Z
D
up
 Z
22
q1
1.
23
{3
0 k
b}
22
,6
81
,9
95
-
22
,7
12
,2
11
GS
TT
1
99
84
14
23
7
D
up
 Z
D
up
 C
D
up
 Z
C:
 c
la
ss
ic
; Z
: Z
-R
TT
; D
el
: d
el
et
io
n;
 D
up
: d
up
lic
at
io
n;
 A
m
p:
 a
m
pl
ifi
ca
tio
n.
*
16
 is
of
or
m
s
J Hum Genet. Author manuscript; available in PMC 2012 January 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Artuso et al. Page 16
Table 3
Genes included in potential modifier regions.
Position Gene Description Function
Chr1:
16,890,300-
16,919,239
ESPNP espin pseudo gene, non-
coding RNA
Unknown
Chr1:
16,954,395-
16,959,139
MSTP9 macrophage stimulating,
pseudogene 9, non-coding
RNA
Unknown
Chr1:
17,121,032-
17,172,061
CROCC ciliary rootlet coiled-coil,
rootletin
Ciliary rootlet formation
Chr1:
195,055,484-
195,067,942
CFHR1 complement factor H-
related
Complement regulation
Chr1:
195,010,553-
195,029,496
CFHR3 complement factor H-
related
Complement regulation
Chr1:
223,741,157-
223,907,468
ENAH enabled homolog
(Drosophila)
Involvement in a range of processes
dependent on cytoskeleton remodelling and
cell polarity such as axon guidance and
lamellipodial and filopodial dynamics in
migrating cells.
Chr2:
3,171,750-
3,360,605
TSSC1 tumor suppressing
subtransferable candidate 1
Possible involvement in tumor
suppression
Chr2:
3,362,453-
3,462,349
TTC15 tetratricopeptide repeat
domain 15.
Possible involvement in autophagy
Chr3:
110,109,340-
110,155,310
GUCA1C guanylate cyclase activator
1C
Ca(2+)-sensitive regulation of guanylyl
cyclase
Chr3:
110,159,777-
110,319,658
MORC1 MORC family CW-type
zinc finger 1
Possible role in spermatogenesis
Chr3:
110,379,702-
110,386,794
C3orf66 chromosome 3 open
reading frame 66, non-
coding RNA
Unknown
Chr5:
848,722-
904,101
ZDHHC11 zinc finger, DHHC-type
containing 11
Probable palmitoyltransferase activity
Chr6:
167,970,520-
168,115,552
MLLT4 myeloid/lymphoid or
mixed-lineage leukemia
Involvement in adhesion system, probably
together with the E-cadherin-catenin system,
which plays a role in the organization of
homotypic, interneuronal and heterotypic cell-
cell adherens junctions
Chr6:
168,136,351-
168,140,606
C6orf54 chromosome 6 open
reading frame 54
Unknown
Chr6:
168,161,402-
168,188,618
KIF25 kinesin family member 25 Possible involvement in microtubule-
dependent molecular transport of organelles
within cells and movement of chromosomes
during cell division.
Chr6:
168,199,313-
168,222,688
FRMD1 FERM domain containing 1 Unknown
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Position Gene Description Function
Chr7:
11,380,696-
11,838,349
THSD7A thrombospondin, type I,
domain containing 7A
Interaction with alpha(V)beta(3)
integrin and paxillin to inhibit
endothelial cell migration and tube
formation.
Chr8:
87,129,807-
87,150,967
PSKH2 protein serine kinase H2 CAMK Ser/Thr protein kinase
Chr8:
87,180,318-
87,234,433
ATP6VOD2 ATPase, H+ transporting,
lysosomal 38kDa, V0
subunit d2
Subunit of the integral membrane V0
complex of vacuolar ATPase that is
responsible for acidifying a variety of
intracellular compartments in
eukaryotic cells, thus providing most of
the energy required for transport
processes in the vacuolar system. May
play a role in coupling of proton
transport and ATP hydrolysis.
Chr10:
46,413,552-
46,420,574
GPRIN2 G protein regulated inducer
of neurite outgrowth 2
Possible role in the control growth of
neurites
Chr10:
46,503,540-
46,508,326
PPYR1 pancreatic polypeptide
receptor 1
It belongs to a family of receptors for
neuropeptide Y involved in a diverse range of
biological actions including
stimulation of food intake, anxiolysis,
modulation of circadian rhythm, pain
transmission and control of
pituitary hormone release.
Chr10:
105,717,460-
105,777,332
SLK STE20-like kinase (yeast) Possible mediation of apoptosis and
actin stress fiber dissolution.
Chr10:
105,781,036-
105,835,628
COL17A1 collagen, type XVII, alpha
1
It encodes the alpha chain of type XVII
collagen that is a structural component of
hemidesmosomes, multiprotein complexes at
the dermal-epidermal
basement membrane zone mediating adhesion
of keratinocytes to the underlying membrane.
Chr22:
41,226,540-
41,238,510
SERHL serine hydrolase-like Possible role in normal peroxisome
function and skeletal muscle growth in
response to mechanical stimuli.
Chr22:
41,279,869-
41,300,332
SERHL2 serine hydrolase-like 2 Probable serine hydrolase. May be
related to muscle hypertrophy.
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